Recently, FDA notified healthcare professionals and patients about the usage of ORLISTAT,.
Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. But the drug is found to be producing some liver associated adverse reactions. During a test conducted between 1999 and October 2008, 32 patients have reported with various liver problems..these include jaundice at the most.

Reference FDA drug news @ www.drugs.com